Skip to content

dr. De Vriese An

Nefrologie
contactgegevens
01/05/2023
Multidisciplinair
InfectieziektenNefrologie

Oral Anticoagulation in Patients With Advanced Chronic Kidney Disease and Atrial Fibrillation: Beyond Anticoagulation.

Mayo Clin Proc. 2023 May;98(5):750-770. doi: 10.1016/j.mayocp.2023.01.007. Epub 2023 Apr 5. PMID: 37028979 Review. dr. De Vriese Andr. Dhaese Sofie
31/10/2022
Laboratoriumgeneeskunde

Immune senescence markers predict the cellular immune response to BNT162b2 vaccination in hemodialysis patients.

Open Forum Infect Dis. 2022 Oct 31;9(11):ofac585dr. Van Praet Jensdr. Emmerechts Jandr. De Vriese Andr. Reynders Stefaandr. Reynders Marijke
01/05/2023
Multidisciplinair
InfectieziektenNefrologie

Oral Anticoagulation in Patients With Advanced Chronic Kidney Disease and Atrial Fibrillation: Beyond Anticoagulation.

Mayo Clin Proc. 2023 May;98(5):750-770. doi: 10.1016/j.mayocp.2023.01.007. Epub 2023 Apr 5.PMID: 37028979 Review.dr. De Vriese An
10/05/2023
Multidisciplinair
InfectieziektenNefrologie

Study protocol of a prospective single-arm multicenter clinical study to assess the safety and performance of the aXess hemodialysis graft: The pivotal study.

J Vasc Access. 2023 May 10:11297298231174932. doi: 10.1177/11297298231174932. Online ahead of print.PMID: 37165650dr. De Vriese An
29/09/2023
Multidisciplinair
InfectieziektenNefrologie

Treatment of IgA Nephropathy: A Rapidly Evolving Field.

J Am Soc Nephrol. 2023 Sep 29. doi: 10.1681/ASN.0000000000000242. Online ahead of print.PMID: 37772889dr. De Vriese An
01/12/2023
Infectieziekten

Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification.

Kidney Int. 2023 Dec;104(6):1092-1102. doi: 10.1016/j.kint.2023.06.032. Epub 2023 Oct 5.PMID: 37795587 Free article.dr. De Vriese An
01/11/2023
Infectieziekten

Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification.

Mayo Clin Proc. 2023 Nov;98(11):1671-1684. doi: 10.1016/j.mayocp.2023.08.006. Epub 2023 Oct 5.PMID: 37804268 Free article.dr. De Vriese An
14/09/2022
Anatomopathologie

Clinicopathological characteristics and disease chronicity in native kidney biopsies in Flanders.

Clin Kidney J. 2022 Sep 14;16(1):125-137. doi: 10.1093/ckj/sfac208. eCollection 2023 Jan.PMID: 36726429 Free PMC article.dr. De Paepe Pascaledr. De Vriese An
01/11/2022
Neurologie

Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications.

Acta Cardiol. 2022 Nov;77(9):791-804. doi: 10.1080/00015385.2021.1976450. Epub 2021 Sep 27. PMID: 34565298dr. Trenson Sanderdr. Demeester Catherinedr. Willandt Barbaradr. Vantomme Nikolaasdr. Van Droogenbroeck Jandr. Delanote Joostdr. Debonnaire Philippedr. De Geeter Frankdr. De Vriese An Tavernier René
12/06/2021
Nefrologie

Humoral and Cellular Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing Home Residents.

Clin Infect Dis. 2021 Dec 6;73(11):2145-2147. doi: 10.1093/cid/ciab300.PMID: 33825869 Free PMC article. No abstract available.dr. Van Praet Jensdr. Vandecasteele Stefaandr. De Vriese Andr. Reynders Marijke
06/12/2023
Nefrologie

Dynamics of the Cellular and Humoral Immune Response After BNT162b2 Messenger Ribonucleic Acid Coronavirus Disease 2019 (COVID-19) Vaccination in COVID-19-Naive Nursing Home Residents.

J Infect Dis. 2021 Nov 22;224(10):1690-1693. doi: 10.1093/infdis/jiab458.PMID: 34514509dr. Van Praet Jensdr. Vandecasteele Stefaandr. De Vriese Andr. Reynders Marijke
01/01/2018
Neurologie

A new imaging technique to monitor disease activity in susac syndrome?

European Stroke Journal. 2018;3:3-204, p. 255dr. De Blauwe Sofiedr. Vanhooren Geertdr. De Vriese Andr. Lafaut Bartdr. Casselman Jan
06/05/2020
Nefrologie

IgG Antibody Response to SARS-Co-V-2 Infection and Viral RNA Persistence in Patients on Maintenance Hemodialysis.

Am J Kidney Dis 2020dr. De Vriese Andr. Reynders Marijke
01/01/2022
Nefrologie

Epidemiology of native kidney disease in Flanders: results from the FCGG kidney biopsy registry.

Clin Kidney J 2022; 15: 1361-1372dr. De Vriese An
01/01/2021
Nefrologie

Acute glomerulonephritis.

Lancet 2022; 399 (10335): 1646-1663dr. De Vriese An
01/01/2021
Nefrologie

Covid-19 in dialysis: clinical impact, immune response, prevention and treatment.

Kidney Int 2022; 101:883-894dr. De Vriese An
06/12/2023
Laboratoriumgeneeskunde

“Predictors and dynamics of the humoral and cellular immune response to SARS-CoV-2 vaccination in hemodialysis patients: a multicenter observational study”

J Am Soc Nephrol. 2021 Sep 29: ASN.2021070908. doi:10.1681/ASN.2021070908.dr. Van Praet Jensdr. De Vriese Andr. Reynders Marijke
06/12/2023
Laboratoriumgeneeskunde

“Dynamics of the cellular and humoral immune response after BNT162b2 mRNA Covid-19 vaccination in Covid-19 naive nursing home residents”

J Infect Dis. 2021 Sep 13:jiab458.doi: 10.1093/infdis/jiab458. Online ahead of print.dr. Van Praet Jensdr. Vandecasteele Stefaandr. De Vriese Andr. Reynders Marijke
06/12/2023
Laboratoriumgeneeskunde

“Longevity and correlation with disease severity of the humoral and cellular response to SARS-CoV-2 infection in haemodialysis patients”

Clinical Kidney Journal. 2021 Aug 13;14(11):2446-2448. doi:10.1093/ckj/sfab147. eCollection 2021 Nov.dr. Van Praet Jensdr. De Vriese Andr. Reynders Marijke
04/07/2021
Laboratoriumgeneeskunde

“Humoral and cellular immunogenicity of the BNT162b2 mRNA Covid-19 Vaccine in nursing home residents”

Clin Infect Dis. 2021 Apr 7:ciab300. doi: 10.1093/cid/ciab300.dr. Van Praet Jensdr. Vandecasteele Stefaandr. De Vriese Andr. Reynders Marijke
01/01/2021
Nefrologie

Noninvasive diagnosis of PLA2R-associated membranous nephropathy: a validation study.

Clin J Am Soc Nephrol 2021.dr. De Vriese An
01/01/2021
Nefrologie

Longevity and correlation with disease severity of the humoral and cellular response to SARS-CoV-2 infection in hemodialysis patients.

Clin Kidney J 2021; 14: 2446-2448.dr. Van Praet Jensdr. De Vriese Andr. Reynders Marijke
01/01/2021
Nefrologie

Predictors and dynamics of the humoral and cellular immune response to SARS-CoV-2 mRNA vaccines in hemodialysis patients: a multicenter observational study.

J Am Soc Nephrol 2021.dr. Van Praet Jensdr. De Vriese Andr. Reynders Marijke
01/01/2021
Nefrologie

Dynamics of the cellular and humoral immune response after BNT162b2 mRNA Covid-19 vaccination in Covid-19 naive nursing home residents.

J Infect Dis 2021.dr. Van Praet Jensdr. Vandecasteele Stefaandr. De Vriese Andr. Reynders Marijke
01/01/2021
Nefrologie

Authors’ Reply.

J Am Soc Nephrol 2021; 32: 2390-2391.dr. De Vriese An
01/01/2021
Nefrologie

Therapeutic trials in adult FSGS: lessons learned and the road forward.

Nat Rev Nephrol 2021; 17: 619-630.dr. De Vriese An
01/01/2021
Nefrologie

Humoral and cellular immunogenicity and safety of the BNT162b2 mRNA Covid-19 Vaccine in nursing home residents.

Clin Inf Dis 2021.dr. Van Praet Jensdr. Vandecasteele Stefaandr. De Vriese Andr. Reynders Marijke
01/01/2021
Nefrologie

Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial.

J Am Soc Nephrol 2021; 32: 1474-1483.dr. Van Der Meersch Hansdr. De Vriese An
01/01/2021
Nefrologie

A target antigen-based approach to the classification of membranous nephropathy.

Mayo Clin Proc 2021; 96: 577-591.dr. De Vriese An
01/01/2021
Nefrologie

Anticoagulation management in hemodialysis patients with atrial fibrillation: evidence and opinion.

Nephrol Dial Transplant 2021.dr. De Vriese An
01/01/2021
Nefrologie

Incidence, characteristics and outcome of Covid-19 in adult patients on kidney replacement therapy: a region-wide cohort study.

J Am Soc Nephrol 2021; 32: 385-396.dr. De Vriese An
01/01/2021
Nefrologie

PEXIVAS: The end of plasmapheresis for ANCA-associated vasculitis?

Clin J Am Soc Nephrol 2021; 16: 307-309.dr. De Vriese An
06/12/2023
Cardiologie

Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications.

Acta Cardiol. 2021 Sep 27:1-14. doi: 10.1080/00015385.2021.1976450.dr. Willandt Barbaradr. Vantomme Nikolaasdr. Van Droogenbroeck Jandr. De Paepe Pascaledr. Delanote Joostdr. De Geeter Frankdr. De Vriese An Tavernier Renédr. Van Meirhaeghe Jandr. Lambert Greet
06/12/2023
Cardiologie

Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications.

Acta Cardiol. 2021 Sep 27:1-14.dr. Willandt Barbaradr. Vantomme Nikolaasdr. Van Droogenbroeck Jandr. De Paepe Pascaledr. Delanote Joostdr. Debonnaire Philippedr. De Geeter Frankdr. De Vriese An Tavernier Renédr. Van Meirhaeghe Jan
06/12/2023
Cardiologie

Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications.

Acta Cardiol. 2021 Sep 27:1-14.dr. Willandt Barbaradr. Vantomme Nikolaasdr. Van Droogenbroeck Jandr. De Paepe Pascaledr. Delanote Joostdr. Debonnaire Philippedr. De Geeter Frankdr. De Vriese An Tavernier Renédr. Van Meirhaeghe Jan
01/01/2012
Neurologie

Reversion of cerebral artery stenoses due to tuberculomas with TNF-alpha antibodies.

Clin Neurol Neurosurg. 2012;114:1016-1018 (doi:10.1016/j.clineuro.2012.01.027)dr. Vandecasteele Stefaandr. Vanhooren Geertdr. De Vriese An
01/01/2021
Nefrologie

Incidence, characteristics and outcome of Covid-19 in adult patients on kidney replacement therapy: a region-wide cohort study.

J Am Soc Nephrol 2020dr. De Vriese An
01/01/2020
Nefrologie

Standardized Reporting of Monoclonal Immunoglobulin-Associated Renal Diseases: Recommendations from a Mayo Clinic/Renal Pathology Society Working Group.

Kidney Int 2020; 98: 310-313.dr. De Vriese An
06/12/2023
Nefrologie

In Reply to ‘Is SARS-CoV-2 Serology Relevant for Hemodialysis Patients With COVID-19?’

Am J Kidney Dis 2020.dr. De Vriese Andr. Reynders Marijke
06/12/2023
Laboratoriumgeneeskunde

“In Reply to ‘Is SARS-CoV-2 Serology Relevant for Hemodialysis Patients With COVID-19?”

Am J Kidney Dis. 2020 Jun 27:S0272-6386(20)30783-6. doi:10.1053/j.ajkd.2020.06.005dr. De Vriese Andr. Reynders Marijke
06/05/2020
Laboratoriumgeneeskunde

“IgG Antibody Response to SARS-CoV-2 Infection and Viral RNA Persistence in Patients on Maintenance Hemodialysis “.

American Journal of Kidney Diseases. 2020 Jun 5:S0272-6386(20)30733-2. doi: 10.1053/j.ajkd.2020.05.009.dr. De Vriese Andr. Reynders Marijke
11/08/2019
Radiologie en Medische Beeldvorming

Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study.

J Am Soc Nephrol. 2019 Nov 8. pii: ASN.2019060579. doi: 10.1681/ASN.2019060579. [Epub ahead of print] PMID: 31704740 Select item 296314983.dr. Delanote Joostdr. De Vriese An
Nefrologie

Other consequences from monoclonal immunoglobulins/fragments. Membranoproliferative glomerulonephritis and acquired Fanconi syndrome.

In: The Oxford Textbook of Clinical Nephrology.dr. De Vriese An
Nefrologie

Membranoproliferative glomerulonephritis and cryoglobulinemic glomerulonephritis.

In: Comprehensive Clinical Nephrology, 6th Edition. Edited by John Feehally, Rick Johnson, Jürgen Floege, Marcello Tonelli.dr. De Vriese An
Nefrologie

The approach to the patient with glomerular disease.

In: Scientific American Nephrology Dialysis and Transplantation.dr. De Vriese An
Nefrologie

Membranous nephropathy.

In: National Kidney Foundation’s Primer on Kidney Diseases, 7th Edition. Edited by Scott Gilbert, Daniel Weiner, Andrew Bomback, Mark Perazella, Marcello Tonelli, pp. 188-197. ISBN: 978-0-323-47794-9dr. De Vriese An
Nefrologie

Membranoproliferative glomerulonephritis.

In: Current Progress in Nephrology. Edited by Claudio Ponticelli and R Kasi Visweswaran, pp. 57-78. ISBN: 978-93-83989-19-5dr. De Vriese An
Nefrologie

Membranous nephropathy.

In: Oxford Textbook of Medicine.dr. De Vriese An
Nefrologie

Glomerular diseases.

In: Cecil Essentials of Medicine. Edited by IJ Benjamin, pp 314-328. ISBN: 978-0-323-29617-5dr. De Vriese An
Nefrologie

Indications to start kidney replacement therapy.

In: Management of acute kidney problems. Edited by A Jorres, C Ronco and Kellum, pp 471-479. ISBN: 978-3-540-69413-7dr. De Vriese An
01/01/2002
Nefrologie

Connexin-mimetic peptides: Influence on nitric oxide synthase- and cyclooxygenase-independent renal vasodilatation, basal renal blood flow and blood pressure in the rat.

In: EDHF 2002. Edited by PM VANHOUTTE, pp 78-86. ISBN 0-415-30853-4dr. De Vriese An
01/01/2000
Nefrologie

Folate restores the NO synthase- and cyclooxygenase-resistant renal vasodilator response to acetylcholine in diabetes.

In: EDHF 2000. Edited by PM VANHOUTTE, pp 360-369. ISBN 0-415-26904-0dr. De Vriese An
Nefrologie

Factors influencing the progression of diabetic nephropathy.

In: Diabetic Nephropathy. Edited by J BONER, M COOPER, pp 75-96. ISBN 1-84184-076-9dr. De Vriese An
01/01/1999
Nefrologie

Acute renal failure in natural disasters.

In: Acute renal failure: a companion to Brenner & Rector’s the kidney. Edited by B MOLITORIS, W FINN, pp 236-245. ISBN 0-7216-9174-9dr. De Vriese An
01/01/1999
Nefrologie

Continuous renal replacement therapies in sepsis: do they matter?

In: Yearbook of Intensive Care and Emergency Medicine 1999, Edited by JL VINCENT, pp 611-620. ISSN 0942-5381.dr. De Vriese An
01/01/1992
Nefrologie

Influence of vasoactive intestinal polypeptide and NG-nitro-L-argininemethylester on cholinergic neurotransmission in the rat gastric fundus.

Eur J Pharmacol 1992; 221: 235-242.dr. De Vriese An
01/01/1995
Nefrologie

Carbamazepine hypersensitivity syndrome: report of 4 cases and review of the literature.

Medicine 1995; 74: 144-151dr. De Vriese An
01/01/1997
Nefrologie

Severe acute renal failure due to bromate intoxication: report of a case and discussion of management guidelines based on a review of the literature.

Nephrol Dial Transplant 1997; 12: 204-209.dr. De Vriese An
01/01/1998
Nefrologie

Rifampicin-associated acute renal failure: pathophysiologic, immunologic and clinical features.

Am J Kidney Dis 1998; 31: 108-115.dr. De Vriese An
01/01/1997
Nefrologie

Fundus fluorescein angiography in hypertensive renal failure.

Graefe Arch Clin Exp Ophtalmol 1997; 235: 749-754.dr. De Vriese An
01/01/1998
Nefrologie

Mild to moderate hyperhomocysteinaemia in cardiovascular disease.

Acta Cardiologica 1998; 53: 337-344.dr. De Vriese An
01/01/1999
Nefrologie

Cytokine removal during continuous hemofiltration in septic patients.

J Am Soc Nephrol 1999; 10: 846-853.dr. De Vriese An
01/01/1999
Nefrologie

Can inflammatory mediators be removed efficiently by continuous renal replacement techniques?

Intensive Care Med 1999; 25: 903-910.dr. De Vriese An
01/01/1999
Nefrologie

Evidence based therapy of acute renal failure.

Acta Clin Belg 1999; 54: 263-273.dr. De Vriese An
01/01/1999
Nefrologie

The role of selectins in glomerular leukocyte adhesion in rat anti-glomerular basement membrane glomerulonephritis.

J Am Soc Nephrol 1999; 10: 2510-2517.dr. De Vriese An
01/01/2000
Nefrologie

The role of dialyzer biocompatibility in acute renal failure.

Blood Purif 2000; 18: 1-12.dr. De Vriese An
01/01/2000
Nefrologie

Off-line analysis of red blood cell velocity in renal arterioles.

J Vasc Res 2000; 37: 26-31.dr. De Vriese An
01/01/2000
Nefrologie

Endothelial dysfunction in diabetes.

Br J Pharmacol 2000; 130: 963-974.dr. De Vriese An
01/01/2000
Nefrologie

The impaired renal vasodilator response attributed to endothelium-derived hyperpolarizing factor in streptozotocin-induced diabetic rats is restored by 5-methyltetrahydrofolate.

Diabetologia 2000; 43: 1116-1125.dr. De Vriese An
01/01/2001
Nefrologie

Intravital microscopy: an integrated evaluation of peritoneal function and structure.

Nephrol Dial Transplant 2001; 16: 657-660.dr. De Vriese An
01/01/2001
Nefrologie

Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes.

J Am Soc Nephrol 2001; 12: 993-1000.dr. De Vriese An
01/01/2001
Nefrologie

Evidence-based treatment of hypertension in diabetes type 2.

Acta Clin Belg 2001; 56: 96-102.dr. De Vriese An
01/01/2001
Nefrologie

Diabetes-induced renal microvascular dysfunction in the hydronephrotic kidney: role of nitric oxide.

Kidney Int 2001; 60: 202-210.dr. De Vriese An
01/01/2001
Nefrologie

Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane.

J Am Soc Nephrol 2001; 12: 1734-1741.dr. De Vriese An
01/01/2001
Nefrologie

Adsorption techniques and the use of sorbents.

Contrib Nephrol 2001; 133: 140-153.dr. De Vriese An
01/01/2001
Nefrologie

Neoangiogenesis in the peritoneal membrane: does it play a role in ultrafiltration failure ?

Nephrol Dial Transplant 2001; 16: 2143-2145.dr. De Vriese An
01/01/2001
Nefrologie

Glucotoxicity of the peritoneal membrane: the case for VEGF.

Nephrol Dial Transplant 2001; 16: 2299-2302dr. De Vriese An
01/01/2002
Nefrologie

Effects of connexin-mimetic peptides on nitric oxide synthase- and cyclooxygenase-independent renal vasodilatation, basal renal blood flow and blood pressure.

Kidney Int 2002; 61: 177-185.dr. De Vriese An
01/01/2002
Nefrologie

Hemodynamic effects of conventional and new peritoneal dialysis solutions on the microcirculation of the rat peritoneal membrane. Role of acidity, buffer choice, glucose concentration and glucose degradation products.

J Am Soc Nephrol 2002; 13: 480-489.dr. De Vriese An
01/01/2001
Nefrologie

Non anticoagulant effects of heparin: implications for animal models of peritoneal dialysis.

Perit Dial Int 2001; 21 (Suppl 3): S354-S356.dr. De Vriese An
01/01/2001
Nefrologie

What happens to the peritoneal membrane in long-term peritoneal dialysis ?

Perit Dial Int 2001; 21 (Suppl 3): S3-S12.dr. De Vriese An
01/01/2002
Nefrologie

Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure?

Kidney Int 2002; 61: 1199-1209.dr. De Vriese An
01/01/2002
Nefrologie

Why are homocysteine levels elevated in renal failure? A metabolic approach.

J Lab Clin Med 2002; 139: 262-268.dr. De Vriese An
01/01/2002
Nefrologie

Experimental diabetes induces functional and structural changes in the peritoneum.

Kidney Int 2002; 62: 668-678.dr. De Vriese An
01/01/2002
Nefrologie

Compensatory glomerular hypertrophy following unilateral nephrectomy is strictly VEGF dependent.

Am J Physiol Endocrinol Metab 2002; 283: E362-366.dr. De Vriese An
01/01/2002
Nefrologie

Comparison of the radioiodinated serum albumin (RISA) dilution technique with direct volumetric measurements in animal models of peritoneal dialysis.

Perit Dial Int 2002; 22: 316-322.dr. De Vriese An
01/01/2002
Nefrologie

Amelioration of long-term renal changes in obese type 2 diabetic mice with a neutralizing vascular endothelial growth factor (VEGF)-antibody.

Diabetes 2002; 51: 3090-3094.dr. De Vriese An
01/01/2002
Nefrologie

Molecular imaging of early events in the development of the diabetic cardiomyopathy.

Amino Acids 2002; 23: 331-336.dr. De Vriese An
01/01/2002
Nefrologie

Interesting news in peritoneal dialysis.

Nephron 2002; 92: 763-771.dr. De Vriese An
01/01/2002
Nefrologie

The effects of heparin administration in an animal model of chronic dialysate exposure.

Perit Dial Int 2002; 22: 566-572.dr. De Vriese An
01/01/2002
Nefrologie

Increased leukocyte rolling in newly formed mesenteric vessels in the rat peritoneal membrane during peritoneal dialysis.

Perit Dial Int 2002; 22: 655-662.dr. De Vriese An
01/01/2003
Nefrologie

The statement that folate supraphysiological levels in uremic patients do not cause harm should not go unchallenged.

Kidney Int 2003; 63 :771-773.dr. De Vriese An
01/01/2003
Nefrologie

Recent concepts in the molecular biology of the peritoneal membrane – Implications for more biocompatible dialysis solutions.

Blood Purif 2003; 21: 14-23.dr. De Vriese An
01/01/2003
Nefrologie

Prevention and treatment of acute renal failure in sepsis.

J Am Soc Nephrol 2003; 14: 792-805dr. De Vriese An
01/01/2003
Nefrologie

Renal angiomyolipoma in association with pulmonary lymphangioleiomyomatosis.

Am J Kidney Dis 2003; 41: 877-883.dr. De Vriese An
01/01/2003
Nefrologie

Effects of conventional and new peritoneal dialysis solutions on leukocyte recruitment in the microcirculation of the rat peritoneal membrane.

J Am Soc Nephrol 2003; 14: 1296-1306.dr. De Vriese An
01/01/2003
Nefrologie

Extensive acronecrosis as a manifestation of mixed cryoglobulinemia.

Acta Clin Belg 2003; 58: 58-61.dr. De Vriese An
01/01/2003
Nefrologie

Peritoneal microcirculation.

Contrib Nephrol 2003; 140: 56-69.dr. De Vriese An
01/01/2003
Nefrologie

Inhibition of AGE-RAGE interaction prevents hyperglycemia-induced fibrosis of the peritoneal membrane.

J Am Soc Nephrol 2003; 14: 2109-2118.dr. De Vriese An
01/01/2003
Nefrologie

The emerging role of VEGF in diabetic kidney disease.

Nephrol Dial Transplant 2003; 18: 1427-1430.dr. De Vriese An
01/01/2003
Nefrologie

Intravital videomicroscopy in peritoneal dialysis research.

Nefrologia 2003; 23 Suppl 3: 28-31.dr. De Vriese An
01/01/2003
Nefrologie

Antibiotic administration in an animal model of chronic dialysate exposure.

Perit Dial Int 2003; 23: 331-338.dr. De Vriese An
01/01/2003
Nefrologie

Creatine-supplementation decreases homocysteine in an animal model of uremia.

Kidney Int 2003; 64: 1331-1337.dr. De Vriese An
01/01/2003
Nefrologie

Effect of dialyzer membrane pore size on plasma homocysteine levels in hemodialysis patients.

Nephrol Dial Transplant 2003; 18: 2596-2600.dr. De Vriese An
01/01/2003
Nefrologie

Pharmacologic treatment of acute renal failure in sepsis.

Curr Opin Crit Care 2003; 9: 474-480.dr. De Vriese An
01/01/2003
Nefrologie

Prevention and nondialytic treatment of acute renal failure.

Curr Opin Crit Care 2003; 9: 481-490.dr. De Vriese An
01/01/2004
Nefrologie

Long-term renal changes in the Goto-Kakizaki rat, a model of lean type 2 diabetes.

Nephrol Dial Transplant 2004; 19: 1092-1097.dr. De Vriese An
01/01/2004
Nefrologie

Vascular hyporesponsiveness in the mesenteric artery of anaesthetized rats with cirrhosis and portal hypertension: an in-vivo study.

Eur J Gastroenterol Hepatol 2004; 16: 139-145.dr. De Vriese An
01/01/2004
Nefrologie

Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis: support for a risk in cirrhotic patients.

Liver Int 2004; 24: 63-68.dr. De Vriese An
01/01/2004
Nefrologie

Endothelium-derived hyperpolarizing factor – mediated renal vasodilatory response is impaired during acute and chronic hyperhomocysteinemia.

Circulation 2004; 109: 2331-2336.dr. De Vriese An
01/01/2004
Nefrologie

The effects of peritoneal dialysate solutions on peritoneal host defense.

Perit Dial Int 2004; 24: 123-138.dr. De Vriese An
01/01/2004
Nefrologie

Prohepcidin accumulates in renal insufficiency.

Clin Chem Lab Med 2004; 42: 387-389.dr. De Vriese An
01/01/2004
Nefrologie

The role of vascular endothelial growth factor in renal pathophysiology.

Kidney Int 2004; 65: 2003-2017.dr. De Vriese An
01/01/2004
Nefrologie

Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane.

Kidney Int 2004; 66: 1257-1265.dr. De Vriese An
01/01/2005
Nefrologie

Analytical and biochemical aspects associated with supraphysiological creatine intake.

Clin Chim Acta 2005; 351: 217-219.dr. De Vriese An
01/01/2004
Nefrologie

Creatine supplementation does not decrease total plasma homocysteine in chronic hemodialysis patients.

Kidney Int 2004; 66: 2422-2428.dr. De Vriese An
01/01/2004
Nefrologie

From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines.

Endocrine Rev 2004; 25: 971-1010.dr. De Vriese An
01/01/2005
Nefrologie

Cytochrome P450-2C11 mRNA is not expressed in endothelial cells dissected from rat renal arterioles.

Nephron Physiol 2005; 99: 43-49.dr. De Vriese An
01/01/2005
Nefrologie

Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes.

Horm Metab Res 2005; 37: 21-25.dr. De Vriese An
01/01/2004
Nefrologie

The role of hyperhomocysteinemia in relation to nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDHF)-mediated vasodilatation.

Cell Mol Biol 2004; 50: 911-916.dr. De Vriese An
01/01/2005
Nefrologie

The John F. Maher recipient lecture 2004: RAGE in the peritoneum.

Perit Dial Int 2005; 25: 8-11.dr. De Vriese An
01/01/2005
Nefrologie

Animal models in peritoneal dialysis research: a need for consensus.

Perit Dial Int 2005; 25: 16-24.dr. De Vriese An
01/01/2005
Nefrologie

Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered peritoneal dialysis solution in a rat model.

Kidney Int 2005; 76: 1559-1565.dr. De Vriese An
01/01/2005
Nefrologie

Immunopathological changes in a uraemic rat model for peritoneal dialysis.

Nephrol Dial Transplant 2005; 20: 1350-1361.dr. De Vriese An
01/01/2005
Nefrologie

Pathophysiological role of vascular endothelial growth factor in the remnant kidney.

Nephron Exp Nephrol 2005; 101: e9-15.dr. De Vriese An
01/01/2005
Nefrologie

Effects of new peritoneal dialysis solutions on leukocyte recruitment in the rat peritoneal membrane.

Nephron Exp Nephrol 2005; 101: e139-e145.dr. De Vriese An
01/01/2005
Nefrologie

Management of therapy-resistant systemic lupus erythematosus with rituximab: report of a case and review of the literature.

Acta Clin Belg 2005; 60: 102-105.dr. De Vriese An
01/01/2006
Nefrologie

A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat.

Nephrol Dial Transplant 2006; 21: 324-329.dr. De Vriese An
01/01/2005
Nefrologie

A case of secondary frosted branch angiitis in Behçet’s disease.

Bull Soc Belg Ophtalmol 2005; 298: 41-44.dr. De Vriese An
01/01/2006
Nefrologie

Activation of genes inducing cell-cycle arrest and of increased DNA repair in the hearts of rats with early streptozotocin-induced diabetes mellitus.

Med Sci Monit 2006; 12: BR68-74.dr. De Vriese An
01/01/2006
Nefrologie

Linezolid-induced inhibition of mitochondrial protein synthesis.

Clin Inf Dis 2006; 42: 1111-1117.dr. De Vriese An
01/01/2006
Nefrologie

What did we learn from animal models in peritoneal dialysis ?

Contrib Nephrol 2006; 150: 70-76.dr. De Vriese An
01/01/2006
Nefrologie

Effects of peritoneal dialysis on the vascular bed of the peritoneal membrane.

Contrib Nephrol 2006; 150: 84-89.dr. De Vriese An
01/01/2006
Nefrologie

RAGE-induced myofibroblast transdifferentiation of mesothelial cells contributes to peritoneal fibrosis in uremia.

Nephrol Dial Transplant 2006; 21: 2549-2555.dr. De Vriese An
01/01/2006
Nefrologie

Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study.

Liver Int 2006; 26: 889-898.dr. De Vriese An
01/01/2007
Nefrologie

Diet-induced hyperhomocysteinemia does not lead to large gene expression differences in rat aorta.

Atherosclerosis 2007; 193: 452-454.dr. De Vriese An
01/01/2006
Nefrologie

Current recommendations for diagnosis and management of polyoma BK virus nephropathy in renal transplant recipients.

Nephrol Dial Transplant 2006; 21: 3364-3367.dr. De Vriese An
01/01/2007
Nefrologie

Steroid-resistant sarcoidosis: is antagonism of TNF-α the answer ?

Clin Sci 2007; 112: 281-289.dr. De Vriese An
01/01/2007
Nefrologie

Decreased leukocyte recruitment in the mesenteric microcirculation of rats with cirrhosis is partially restored by treatment with peginterferon: An in vivo study.

J Hepatol 2007; 46: 804-815.dr. De Vriese An
01/01/2007
Nefrologie

Prevention of contrast-induced nephropathy: a critical review.

Curr Opinion Nephrol Hypertens 2007; 16: 336-347.dr. De Vriese An
01/01/2007
Nefrologie

Renal side effects of anti-VEGF therapy in man: a new test system.

Nephrol Dial Transplant 2007, 22: 2778-80.dr. De Vriese An
01/01/2007
Nefrologie

Novel insights in the treatment of diabetic nephropathy.

Acta Clin Belg 2007; 62: 278-290.dr. De Vriese An
01/01/2008
Nefrologie

Guanidinocompounds after creatine supplementation in renal failure patients and their relation to inflammatory status.

Nephrol Dial Transplant 2008; 23: 1330-1335.dr. De Vriese An
01/01/2008
Nefrologie

Oral vitamin C administration increases lipid peroxidation in hemodialysis patients.

Nephron Clin Pract 2008; 108: c28-c34.dr. De Vriese An
01/01/2008
Nefrologie

Autologous transplantation of bone marrow mononuclear cells for limb ischemia in a Caucasian population with atherosclerosis obliterans.

J Intern Med 2008; 263: 395-403.dr. De Vriese An
01/01/2008
Nefrologie

Cellular therapy for critical limb ischemia. Author’s reply.

J Intern Med 2008; 264: 290.dr. De Vriese An
01/01/2009
Nefrologie

Comparison of the prognostic value of dipyridamole and dobutamine myocardial perfusion scintigraphy in end-stage renal disease.

Kidney Int 2009; 76: 428-436.dr. De Vriese An
01/01/2009
Nefrologie

Staphylococcus aureus infections in dialysis: what a nephrologist should know.

Clin J Am Soc Nephrol 2009; 4: 1388-1400.dr. De Vriese An
01/01/2010
Nefrologie

Diffuse alveolar bleeding caused by everolimus.

Chest 2010; 137: 456-459.dr. De Vriese An
01/01/2010
Nefrologie

Recent changes in vancomycin use in renal failure.

Kidney Int 2010; 77: 760-764.dr. De Vriese An
01/01/2011
Nefrologie

Successful treatment of renal AA amyloidosis in familial Mediterranean fever with pegylated -2a interferon.

Clin Nephrol 2011; 75 (Suppl 1): S1-S3.dr. De Vriese An
01/01/2011
Nefrologie

Vancomycin dosing in patients on intermittent hemodialysis.

Semin Dial 2011; 24: 50-55.dr. De Vriese An
01/01/2011
Nefrologie

Fluctuations of haemoglobinaemia in chronic hemodialysis patients.

Acta Clin Belg 2011; 66: 123-128.dr. De Vriese An
01/01/2011
Nefrologie

Implementation of a dose calculator for vancomycin to achieve target through levels of 15-20 mg:ml in persons undergoing hemodialysis.

Clin Inf Dis 2011; 53: 124-129.dr. De Vriese An
01/01/2012
Nefrologie

Should we screen for coronary artery disease in asymptomatic chronic hemodialysis patients ?

Kidney Int 2012; 81: 143-151.dr. De Vriese An
01/01/2012
Nefrologie

Reversion of cerebral artery stenoses due to tuberculomas with TNF-alpha antibodies.

Clin Neurol Neurosurg 2012; 114: 1016-8.dr. De Vriese An
01/01/2013
Nefrologie

The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties.

J Antimicrob Chemother 2013; 68: 743-8.dr. De Vriese An
01/01/2013
Nefrologie

Global protein and histone arginine methylation are affected in a tissue-specific manner in a rat model of diet-induced hyperhomocysteinemia.

Biochim Biophys Acta 2013; 1832: 1708-14.dr. De Vriese An
01/01/2013
Nefrologie

Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall.

J Am Soc Nephrol 2013; 24: 1981-94.dr. De Vriese An
01/01/2014
Nefrologie

Vitamin K2 Supplementation in Hemodialysis Patients: a Randomized Dosefinding Study.

Nephrol Dial Transplant 2014; 29: 1385-90.dr. De Vriese An
01/01/2013
Nefrologie

Cystatin C versus creatinine for kidney function-based risk.

N Engl J Med 2013; 369: 2458-9.dr. De Vriese An
01/01/2014
Nefrologie

Vancomycin: the tale of the vanquisher and the Pyrrhic victory.

Perit Dial Int 2014; 34: 154-61.dr. De Vriese An
01/01/2015
Nefrologie

Hemodialysis catheter design and catheter performance: a randomized controlled trial.

Am J Kidney Dis 2014; 64: 902-8. Erratum in Am J Kidney Dis 2015; 65: 810.dr. De Vriese An
01/01/2014
Nefrologie

A bone scan, no mistake!

J Clin Endocrinol Metab 2014; 99: 4447-8.dr. De Vriese An
01/01/2015
Nefrologie

Dose finding of rivaroxaban in hemodialysis patients.

Am J Kidney Dis 2015; 66: 91-8.dr. De Vriese An
01/01/2015
Nefrologie

High homocysteine induces betaine depletion.

Biosci Rep 2015; 35: pii:e00222.dr. De Vriese An
01/01/2015
Nefrologie

C4d as a diagnostic tool in the diagnosis of proliferative glomerulonephritis.

J Am Soc Nephrol 2015;26:2852-2859.dr. De Vriese An
01/01/2015
Nefrologie

Biomarkers in glomerular diseases: putting the cart before the wheel?

Nephrol Dial Transplant 2015; 30: 885-890.dr. De Vriese An
01/01/2015
Nefrologie

Opponent’s comments.

Nephrol Dial Transplant 2015; 30: 898-899.dr. De Vriese An
01/01/2015
Nefrologie

In reply to “Hemodialysis catheters: which design is more cost-effective? And “Use of an uncensored primary outcome in a catheter design trial”.

Am J Kidney Dis 2015; 66: 171.dr. De Vriese An
01/01/2015
Nefrologie

Glomerular disease caused by dysregulation of the complement alternative pathway: an etiologic approach.

J Am Soc Nephrol 2015; 26: 2917-2929.dr. De Vriese An
01/01/2016
Nefrologie

C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?

J Nephrol 2016; 29: 203-9.dr. De Vriese An
01/01/2016
Nefrologie

Mayo Clinic/ Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of Glomerulonephritis.

J Am Soc Nephrol 2016; 27: 1278-87.dr. De Vriese An
01/01/2016
Nefrologie

Diagnosis of complement alternative pathway disorders.

Kidney Int 2016; 89: 278-288.dr. De Vriese An
01/01/2016
Nefrologie

The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials.

Clin Kidney J 2016; 9: 273-279.dr. De Vriese An
01/01/2016
Nefrologie

The atrial fibrillation conundrum in dialysis patients.

Am Heart J 2016; 174: 111-119.dr. De Vriese An
01/01/2016
Nefrologie

Temporal IgG subtype changes in recurrent idiopathic membranous nephropathy.

Am J Transplant 2016; 16: 2964-72.dr. De Vriese An
01/01/2023
Nefrologie

A proposal for a serology-driven approach to membranous nephropathy.

J Am Soc Nephrol 2017;28:421-430.dr. De Vriese An
01/01/2016
Nefrologie

Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: a meta-analysis.

Am Heart J 2016; 184: 37-46.dr. De Vriese An
01/01/2017
Nefrologie

Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference.

Kidney Int 2017;91:539-551.dr. De Vriese An
01/01/2017
Nefrologie

Fibromuscular dysplasia: results of a multicenter study in Flanders.

Vasa 2017;46:211-218.dr. De Vriese An
01/01/2017
Nefrologie

Proposal for Standardized Grading of Chronic Changes in Native Kidney Biopsy Specimens.

Kidney Int 2017;91:787-789.dr. De Vriese An
01/01/2017
Nefrologie

Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: Results of a proteomic analysis.

Nephrol Dial Transplant 2017;32(suppl_1):i139-i145.dr. De Vriese An
01/01/2017
Nefrologie

What are we missing in the clinical trials of focal segmental glomerulosclerosis?

Nephrol Dial Transplant 2017;32(suppl_1):i14-i21.dr. De Vriese An
01/01/2017
Nefrologie

Should statins be banned from dialysis?

J Am Soc Nephrol 2017;28:1675-1676.dr. De Vriese An
01/01/2017
Nefrologie

Familial antiglomerular basement membrane disease in zero human leukocyte antigen mismatch siblings.

Clin Nephrol 2017;88:277-283.dr. De Vriese An
01/01/2017
Nefrologie

Interstitial immunostaining and renal outcomes in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.

Am J Nephrol 2017;46:231-238.dr. De Vriese An
01/01/2017
Nefrologie

The incidence of primary versus secondary focal and segmental glomerulosclerosis: a clinicopathological study.

Mayo Clin Proc 2017;92:1772-1781.dr. De Vriese An
01/01/2018
Nefrologie

Differentiating primary, genetic and secondary FSGS in adults: a clinicopathologic approach.

J Am Soc Nephrol 2018; 29: 759-774.dr. De Vriese An
01/01/2018
Nefrologie

Measurement of pulse wave velocity, augmentation index and central pulse pressure in atrial fibrillation: a proof of concept study.

J Am Soc Hypertens 2018; 12: 627-632.dr. De Vriese An
01/01/2018
Nefrologie

C3 glomerulopathy: Ten years’ experience at the Mayo Clinic.

Mayo Clin Proc 2018; 93: 991-1008.dr. De Vriese An
01/01/2019
Nefrologie

Non-invasive diagnosis of primary membranous nephropathy using Phospholipase A2 receptor antibodies.

Kidney Int 2019dr. De Vriese An
01/01/2020
Nefrologie

Evaluation of vitamin K status and rationale for vitamin K supplementation in dialysis patients.

Nephrol Dial Transplant 2019.dr. De Vriese An
Infectieziekten

“State of the art treatment of IgA Nephropathy”

Praag2023-09-01dr. De Vriese An
Infectieziekten

“Infectious diseases in Nephrology”

Praag2023-09-01dr. De Vriese An
Nefrologie

Primary vs Secondary Membranous Nephropathy: does it make sense?

Mayo Consensus Meeting on Membranous Nephropathy, Rochester (on-line)2022-10-29dr. De Vriese An
Nefrologie

Device Puncturability.

aXess Pivotal Investigator Meeting Barcelona2022-10-22dr. De Vriese An
Nefrologie

Infectious complications in hemodialysis and peritoneal dialysis.

Nephro Update Europe Amsterdam2022-09-09dr. De Vriese An
Nefrologie

Oral anticoagulation in dialysis.

IVth South-American Conference on Dialysis and Transplantation, Quito2022-06-23dr. De Vriese An
Nefrologie

Oral anticoagulation in CKD: practical questions and pragmatic answers.

Brugge2022-03-18dr. De Vriese An
Nefrologie

Anticoagulation & Atrial fibrillation in CKD.

https://www.youtube.com/watch?v=vlzFdCilljY2022-03-11dr. De Vriese An
Nefrologie

Voor- en nadelen van coumarines vs DOAC.

31e Digitale workshop Nierziekten Papendal (on-line)2020-12-09dr. De Vriese An
Nefrologie

“Infectious complications in hemodialysis and peritoneal dialysis”

Vienna2021-09-11dr. De Vriese An
Nefrologie

“Novel insights in the diagnosis of membranous nephropathy”

Parijs (online)2021-04-27dr. De Vriese An
Nefrologie

“Attenuation of vascular calcification in hemodialysis patients with vitamin K: feasible goal or beautiful fantasy?”

Aachen2020-11-12dr. De Vriese An
Nefrologie

“Infectious complications in hemodialysis and peritoneal dialysis”

Europe, Den Hague2020-09-19dr. De Vriese An
Nefrologie

“Infectious complications in dialysis”

Athene2020-02-28dr. De Vriese An
Nefrologie

“Vitamin K in vascular pathobiology”

Leuven2020-01-16dr. De Vriese An
Nefrologie

“Nephrology 2.0”

Washington DCdr. De Vriese An
Nefrologie

“Infectieziekten in hemodialyse en peritoneale dialyse” en “Anticoagulatie strategieën bij dialyse”

Vaals, Nederlanddr. De Vriese An
Nefrologie

“An update in infectious complications in dialysis patients”.

Praguedr. De Vriese An
Nefrologie

”Limitations of the long-term use of peritoneal dialysis” and ”The prognosis of acute renal failure”.

Iasi (Roemenië)dr. De Vriese An
Nefrologie

“Influence of an anti-CD11b antibody in glomerular hemodynamics and leukocyte adhesion in rat glomerulonephritis”.

Riminidr. De Vriese An
Nefrologie

“Influence of cytokine removal with continuous venovenous hemofiltration (CVVH) on systemic hemodynamics in sepsis”.

Riminidr. De Vriese An
Nefrologie

“Cytokine removal with continuous venovenous hemofiltration (CVVH) in sepsis: relative importance of adsorption and convective elimination”.

Riminidr. De Vriese An
Nefrologie

“The hydronephrotic rat kidney as a model to study the renal microvascular changes in diabetes”.

Tübingendr. De Vriese An
Nefrologie

“Impaired endothelium derived hyperpolarizing factor – mediated renal vasodilatory response in diabetes”.

63ste Wetenschappelijke Vergadering van de Nederlandse Vereniging voor Nefrologie, Arnhemdr. De Vriese An
Nefrologie

“Antibodies against vascular endothelial growth factor decrease hyperfiltration and albuminuria in experimental diabetes”

the XXXVI Congress of the European Renal Association, Madriddr. De Vriese An
Nefrologie

”Endothelial dysfunction in diabetes: a role for folate?”,

Homocysteine Working Group, Nijmegendr. De Vriese An
Nefrologie

“Impaired endothelium-derived hyperpolarizing factor (EDHF) – mediated renal vasodilatory response in diabetes: restoration with folate”

the 32nd Annual Meeting of the American Society of Nephrology, Miamidr. De Vriese An
Nefrologie

“The diabetic rat model to study high glucose-induced peritoneal membrane changes using the videomicroscope system”

PD solutions for the 21st century: experimental and clinical models for evaluation of new PD solutions, Brusselsdr. De Vriese An
Nefrologie

”Diabetes as a model to study the effects of high dialysate glucose levels on peritoneal structure and function”

4th European Peritoneal Dialysis Meeting, 3rd International Meeting on Aminal Models in Peritoneal Dialysis, Madriddr. De Vriese An
Nefrologie

“Hyperpermeability of the peritoneal membrane in diabetes: role of VEGF”

4th European Peritoneal Dialysis Meeting, Madriddr. De Vriese An
Nefrologie

”Role of vascular endothelial growth factor in diabetes”

Symposium Renal Microcirculation, Heidelbergdr. De Vriese An
Nefrologie

“Endothelial dysfunction in the diabetic renal microcirculation: restoration with folate”

XXXVII Congress of the European Renal Association, First combined congres with European Kidney Research Association, Nicedr. De Vriese An
Nefrologie

“Vascular dysfunction in diabetes”

Dresdendr. De Vriese An
Nefrologie

“Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes”

Wetenschappelijke Vergadering van de Nederlandse Vereniging voor Nefrologie, Nijmegendr. De Vriese An
Nefrologie

“Endothelial dysfunction in diabetes”,

Aarhus Kommunehospital, Aarhusdr. De Vriese An
Nefrologie

“Biocompatibility Issues in Peritoneal Dialysis”

5th Course of the Dialysis Academy, Gentdr. De Vriese An
Nefrologie

“How do peritoneal dialysis fluids influence peritoneal vascular reactivity and neoangiogenesis ?”

IX Congress of the International Society for Peritoneal Dialysis, Montréaldr. De Vriese An
Nefrologie

“The effects of heparin administration in an animal model of chronic dialysate exposure”

IX Congress of the International Society for Peritoneal Dialysis, 4th International Meeting on Aminal Models in Peritoneal Dialysis, Montréaldr. De Vriese An
Nefrologie

“Effects of connexin-mimetic peptides on endothelium-derived hyperpolarizing factor (EDHF) – mediated renal vasodilatation, basal renal blood flow and blood pressure”.

XXXVIII Congress of the European Renal Association, Wenendr. De Vriese An
Nefrologie

“Role of glucose degradation products in PD”

7th Course of the Dialysis Academy, Gentdr. De Vriese An
Nefrologie

“Intravital microscopy to evaluate functional properties of standard and pH neutral dialysis solutions”

Fifth European Peritoneal Dialysis Conference, Brusseldr. De Vriese An
Nefrologie

“Mechanisms of glucose toxicity to the peritoneal membrane”

35th Annual Meeting of the American Society of Nephrology, Philadelphiadr. De Vriese An
Nefrologie

“Neoangiogenesis in the peritoneal membrane”

World Congress of Nephrology, Berlindr. De Vriese An
Nefrologie

“The effect of diabetes on the peritoneal membrane: experimental results and clinical correlations”

36th Annual Meeting of the American Society of Nephrology, San Diegodr. De Vriese An
Nefrologie

“RAGE in the peritoneum”

First Joint Meeting of the International Society of Peritoneal Dialysis and the European Peritoneal Dialysis Meeting, Amsterdamdr. De Vriese An
Nefrologie

“On VEGF – the most important growth factor in PD membrane alterations”,

First Joint Meeting of the International Society of Peritoneal Dialysis and the European Peritoneal Dialysis Meeting, Amsterdamdr. De Vriese An
Nefrologie

“Controlling angiogenesis”

7th European Peritoneal Dialysis Meeting, Praagdr. De Vriese An
Nefrologie

“Difficulties in setting up an animal model of peritonitis”,

ANIMOD Meeting, 7th European Peritoneal Dialysis Meeting, Praagdr. De Vriese An
Nefrologie

“Peritoneal and extraperitoneal effects of GDPs and AGEs”

The 11th Congress of the International Society of Peritoneal Dialysis, Hong-Kongdr. De Vriese An
Nefrologie

“Diagnosis and treatment of CAD in ESRD: Can we do better?”

9th European Peritoneal Dialysis Meeting, Strassbourgdr. De Vriese An
Nefrologie

“VEGF in renal pathophysiology”

Conference on Renal Safety, Zurichdr. De Vriese An
Nefrologie

“New insights in pharmacokinetics and pharmacodynamics of antibiotics: implications for the treatment of peritonitis “

49th ERA-EDTA Congress, Parijsdr. De Vriese An
Nefrologie

“Hemodialysis, do we need individualized treatment prescriptions ?”

2nd International Renal Meeting in Sardinia, Cagliaridr. De Vriese An
Nefrologie

“Vitamin K antagonists in dialysis: navigating between Scylla and Charybdis”

First International Renal Conference, Bruggedr. De Vriese An
Nefrologie

“The evidence for intensive dialysis: frequent and prolonged dialysis, hemodiafiltration”, “Vitamin K and vascular calcifications”, and “Hemodialysis catheters: does design matter ?”

Simposio Fronteras 2014, Santiago de Chilidr. De Vriese An
Nefrologie

“Old and new antibiotics in dialysis”

3rd International Renal Meeting in Sardinia, Cagliaridr. De Vriese An
Nefrologie

“Oral anticoagulation in dialysis patients: challenges and opportunities”

Cardiology Divisional Grand Rounds, Mazankowski Alberta Heart Institute, Edmontondr. De Vriese An
Nefrologie

“Oral anticoagulation in dialysis patients”, and “The use of vancomycin in CKD, hemodialysis and peritoneal dialysis”

Srinagardr. De Vriese An
Nefrologie

“Oral anticoagulation in hemodialysis: new insights”

First Mayo Clinic Nephrology Meeting in Argentina, Buenos Airesdr. De Vriese An
Nefrologie

“Should we use vitamin K antagonists in hemodialysis patients?”,

Trondheim Renal Research Group/Norwegian Society of Nephrology, Tröndheimdr. De Vriese An
Nefrologie

“Oral anticoagulation in dialysis: alternatives to warfarin.”

Congres of the Iranian Society of Nephrology, Shirazdr. De Vriese An
Nefrologie

“Oral anticoagulation in hemodialysis patients: challenges and opportunities”

34th Biennal Congres of the Nordic Society of Nephrology, Malmödr. De Vriese An
Nefrologie

“An update in peritoneal dialysis”

Nephro Update Europe, Viennadr. De Vriese An
Nefrologie

“Infectious complications of peritoneal dialysis”

Second International Renal Conference, Bruggedr. De Vriese An
Nefrologie

“Serology-based approach to membranous nephropathy”

Third International Conference on Membranous Nephropathy, Bergamodr. De Vriese An
Nefrologie

“What is new in peritoneal dialysis?” and “Infectious complications in peritoneal dialysis”

Mayo Clinic Meeting, Asuncion, Paraguaydr. De Vriese An
Nefrologie

“An update in peritoneal dialysis”

Nephro Update Europe, Boedapestdr. De Vriese An